本文由小咖机器人翻译整理

期刊来源：N Engl J Med

原文链接：https://doi.org/10.1056/NEJMoa2314390

摘要内容如下：

在这项首次在人类中进行的、研究者发起的开放标签研究中，三名患有复发性胶质母细胞瘤的参与者接受了CARV3-TEAM-E T细胞的治疗，CARV3-TEAM-E T细胞是嵌合抗原受体（CAR）T细胞，通过分泌T细胞结合抗体分子（TEAM），将其改造为靶向表皮生长因子受体（EGFR）变体III肿瘤特异性抗原以及野生型EGFR蛋白。用CARV3-TEAM-E T细胞治疗未导致大于3级的不良事件或剂量限制性毒性作用。放射学肿瘤消退显著而迅速，在接受单次脑室内输注后数天内发生，但三名参与者中有两名的反应是短暂的。（由Gateway for Cancer Research和其他机构资助；Incipient ClinicalTrials.gov编号，NCT05660369。）

英文原文如下：

Abstracts

In this first-in-human, investigator-initiated, open-label study, three participants with recurrent glioblastoma were treated with CARv3-TEAM-E T cells, which are chimeric antigen receptor (CAR) T cells engineered to target the epidermal growth factor receptor (EGFR) variant III tumor-specific antigen, as well as the wild-type EGFR protein, through secretion of a T-cell-engaging antibody molecule (TEAM). Treatment with CARv3-TEAM-E T cells did not result in adverse events greater than grade 3 or dose-limiting toxic effects. Radiographic tumor regression was dramatic and rapid, occurring within days after receipt of a single intraventricular infusion, but the responses were transient in two of the three participants. (Funded by Gateway for Cancer Research and others; INCIPIENT ClinicalTrials.gov number, NCT05660369.).

-----------分割线---------

点击链接：https://www.mediecogroup.com/community/user/vip/categories/ ，成为医咖会员，获取12项专属权益。